Skip to main content

Lynx Completes $4M Private Stock Placement

NEW YORK, Jan. 2 (GenomeWeb News) - Lynx Therapeutics today said it has completed a $4 million private financing of common stock and warrants for common stock.

The financing included the sale of 800,000 newly issued shares of common stock at $5.00 per share and the issuance of warrants to purchase 200,000 shares of common stock at an exercise price of $6.25 per share.

Kevin Corcoran, Lynx's president and CEO, said the company plans to use the financing to expand the commercial usage of its MPSS (Massively Parallel Signature Sequencing) technology.

Lynx completed a $3 million common stock placement in September.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.